Table 1.

Univariate and multivariate analyses of the post-switch outcomes of injection number, change in BCVA, and change in CRT

Outcome		Injection numbers post-switch			BCVA change post-switch (+3M)			CRT change post-switch (+3M)
		Means or estimated coefficient±SD	p-value univariate analysis	p-value multivariate analysis	Means or estimated coefficient±SD	p-value univariate analysis	p-value multivariate analysis	Means or estimated coefficient±SD	p-value univariate analysis	p-value multivariate analysis
Age	Per 10 years	0.01±0.2 (R2 0.00)	0.97		−1.1±0.8 (R2 −0.14)	0.18		−1.9±9.0 (R2 −0.02)	0.83
Gender	Female, n=69	10.8±0.2	0.13		−0.4±0.7	0.50		−38.9±7.4	0.52
	Male, n=29	11.2±0.2			0.4±1.0			−47.6±11.4
Type of CNV	Occult, n=57	11.1±0.2	0.23		−0.8±1.0	0.07		−42.1±8.2	0.88
	Min. classic, n=19	10.8±0.3			−4.7±1.8			−32.6±14.2
	Pred. classic, n=13	10.2±0.4			1.5±2.1			−44.5±17.1
	RAP, n=9	11.0±0.4			2.1±2.6			−51.6±20.6
PED at baseline	Present, n=62	11.1±0.2	0.042*	0.025*	0.4±0.7	0.19	NS	−47.7±7.7	0.18
	Absent, n=36	10.6±0.2			−1.1±0.9			−30.7±10.1
PED at switch time point	Present, n=60	11.1±0.2	0.046*	NS	0.4±0.7	0.17	NS	−53.7±7.7	0.02*	NS
	Absent, n=37	10.6±0.2			−1.2±0.9			−23.2±9.8
	Missing data, n=1
BCVA change from baseline to Month 3 post RZB		−0.00±0.01 (R2 −0.02)	0.88		0.01±0.05 (R2 0.01)	0.91		−0.40±0.58 (R2 −0.07)	0.48
BCVA change from Month 3 post RZB to switch		0.01±0.01 (R2 0.05)	0.88		−0.07±0.04 (R2 −0.17)	0.10	NS	0.16±0.47 (R2 0.04)	0.73
CRT change from baseline to Month 3 post RZB		0.00±0.00 (R2 0.04)	0.73		0.01±0.01 (R2 0.13)	0.19	NS	−0.03±0.08 (R2 −0.04)	0.68
CRT change from Month 3 post RZB to switch		0.00±0.00 (R2 0.09)	0.36		−0.00±0.01 (R2 −0.06)	0.55		−0.25±0.05 (R2 −0.47)	<0.0001*	<0.0001*
Dryness of SD-OCT at Month 3 post RZB	Dry, n=47	10.8±0.2	0.29		0.2±0.8	0.57		−43.7±8.9	0.73
	Fluid, n=51	11.1±0.2			−0.5±0.8			−39.4±8.6
Number of injections during first 12 months post RZB	Per injection	0.17±0.05 (R2 0.35)	0.0004*	0.0002*	−0.04±0.20 (R2 −0.02)	0.83		−0.15±2.23 (R2 −0.01)	0.95
Duration of treatment before switch	Per month	0.00±0.01 (R2 −0.05)	0.61		0.02±0.03 (R2 0.07)	0.50		−0.23±0.33 (R2 −0.07)	0.49

Notes:

^*Statistically significant value.

Abbreviations: +3M, 3 months post-switch; BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; CRT, central retinal thickness; NS, not significant; PED, pigment epithelium detachment; RAP, retinal angiomatous proliferation; R², correlation factor; RZB, ranibizumab; SD-OCT, spectral domain optical coherence tomography.